JOP20210332A1 - عقاقير أولية لمعدلات المستقبل nmda - Google Patents

عقاقير أولية لمعدلات المستقبل nmda

Info

Publication number
JOP20210332A1
JOP20210332A1 JOP/2021/0332A JOP20210332A JOP20210332A1 JO P20210332 A1 JOP20210332 A1 JO P20210332A1 JO P20210332 A JOP20210332 A JO P20210332A JO P20210332 A1 JOP20210332 A1 JO P20210332A1
Authority
JO
Jordan
Prior art keywords
modulators
nmda receptor
prodrugs
compounds
directed
Prior art date
Application number
JOP/2021/0332A
Other languages
English (en)
Inventor
Mauro Marigo
Erhad Ascic
Laurent David
John Paul Kilburn
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of JOP20210332A1 publication Critical patent/JOP20210332A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بعقاقير أولية جديدة بالصيغة (I) لمعدلات المستقبل NMDA. وتتعلق جوانب منفصلة من الاختراع بتركيبات صيدلية تحتوي على المركبات المذكورة، واستخدامات المركبات لعلاج الاضطرابات العصبية أو الاضطرابات النفسية العصبية مثل الاكتئاب.
JOP/2021/0332A 2019-07-03 2020-07-01 عقاقير أولية لمعدلات المستقبل nmda JOP20210332A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201900822 2019-07-03
PCT/EP2020/068513 WO2021001420A1 (en) 2019-07-03 2020-07-01 Prodrugs of modulators of the nmda receptor

Publications (1)

Publication Number Publication Date
JOP20210332A1 true JOP20210332A1 (ar) 2023-01-30

Family

ID=71614856

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0332A JOP20210332A1 (ar) 2019-07-03 2020-07-01 عقاقير أولية لمعدلات المستقبل nmda

Country Status (20)

Country Link
US (2) US11358971B2 (ar)
EP (1) EP3994140A1 (ar)
JP (1) JP2022538180A (ar)
KR (1) KR20220034052A (ar)
CN (1) CN114008053A (ar)
AR (1) AR119341A1 (ar)
AU (1) AU2020299410A1 (ar)
BR (1) BR112021003983A2 (ar)
CA (1) CA3144303A1 (ar)
CL (1) CL2021003534A1 (ar)
CO (1) CO2021017154A2 (ar)
CR (1) CR20210663A (ar)
EC (1) ECSP22003599A (ar)
IL (1) IL289576A (ar)
JO (1) JOP20210332A1 (ar)
MA (1) MA56450A (ar)
MX (1) MX2021015752A (ar)
PE (1) PE20220136A1 (ar)
TW (1) TW202116780A (ar)
WO (1) WO2021001420A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
EP0743853B1 (en) 1994-02-08 2001-05-02 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU723349B2 (en) 1996-06-07 2000-08-24 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1998056752A1 (en) 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
US8993591B2 (en) * 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) * 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
PT3386591T (pt) * 2015-12-09 2020-10-01 Cadent Therapeutics Inc Moduladores de recetores nmda heteroaromáticos e suas utilizações
US11274107B2 (en) * 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor

Also Published As

Publication number Publication date
PE20220136A1 (es) 2022-01-27
ECSP22003599A (es) 2022-02-25
CA3144303A1 (en) 2021-01-07
CR20210663A (es) 2022-02-22
TW202116780A (zh) 2021-05-01
AR119341A1 (es) 2021-12-09
IL289576A (en) 2022-03-01
US20210047342A1 (en) 2021-02-18
EP3994140A1 (en) 2022-05-11
AU2020299410A1 (en) 2022-02-03
CL2021003534A1 (es) 2022-08-19
CN114008053A (zh) 2022-02-01
BR112021003983A2 (pt) 2022-03-15
US11358971B2 (en) 2022-06-14
MA56450A (fr) 2022-05-11
CO2021017154A2 (es) 2022-01-17
WO2021001420A1 (en) 2021-01-07
US20220213117A1 (en) 2022-07-07
MX2021015752A (es) 2022-01-27
JP2022538180A (ja) 2022-08-31
KR20220034052A (ko) 2022-03-17

Similar Documents

Publication Publication Date Title
BR112018013827A2 (pt) moduladores de 5?-nucleotidase, ecto e uso dos mesmos
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
AU2018243836A1 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
CR20220207A (es) Compuestos terapéuticos y métodos de uso
EA202091428A1 (ru) Замещенные амиды ii пирролидина
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
MX2021011008A (es) Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.
MX2021000759A (es) Derivados de triazolquinoxalina adicionalmente sustituidos.
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
WO2020092102A3 (en) 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of the m4 muscarinic acetylcholine receptor
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
CR20200346A (es) Oligonucleótidos para modular la expresión de tmem106b
JOP20210332A1 (ar) عقاقير أولية لمعدلات المستقبل nmda
JOP20210331A1 (ar) مُعَدِّلات مُستقبِل نمدا (nmda)
WO2022129047A3 (en) Modulators of the nmda receptor
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
MX2020009097A (es) Compuestos que modulan la funcion del receptor de ampa.
EA202091429A1 (ru) Замещенные амиды i пирролидина
PH12021550258A1 (en) Cdk8/19 inhibitors
JOP20210091A1 (ar) مشتقات أريل سلفونيل بيرول كربوكساميد على هيئة عوامل تنشيط قناة بوتاسيوم Kv3
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.